A5067983218- SARS-CoV-2 and COVID-19 Research
- HIV Research and Treatment
- SARS-CoV-2 detection and testing
- COVID-19 Clinical Research Studies
- HIV/AIDS drug development and treatment
- interferon and immune responses
- Immune Cell Function and Interaction
- HIV/AIDS Research and Interventions
- CRISPR and Genetic Engineering
- COVID-19 epidemiological studies
- Biosensors and Analytical Detection
- Animal Virus Infections Studies
- Nuclear Structure and Function
- Bacteriophages and microbial interactions
- Biochemical and Molecular Research
- RNA Research and Splicing
- Virus-based gene therapy research
- Viral gastroenteritis research and epidemiology
- Long-Term Effects of COVID-19
- Public Health and Environmental Issues
- Infection Control and Ventilation
- Advanced biosensing and bioanalysis techniques
- Hepatitis C virus research
- Virology and Viral Diseases
- Microbial infections and disease research
Universidad de Las Palmas de Gran Canaria
2023-2024
King's College London
2015-2022
The London College
2021
London Bridge Hospital
2021
Guy's Hospital
2021
Centro de Biología Molecular Severo Ochoa
2010-2015
Universidad Autónoma de Madrid
2010-2015
Consejo Superior de Investigaciones Científicas
2010-2015
Associação Brasileira de Oncologia Veterinária
2012
Antibody responses to SARS-CoV-2 can be detected in most infected individuals 10-15 d after the onset of COVID-19 symptoms. However, due recent emergence human population, it is not known how long antibody will maintained or whether they provide protection from reinfection. Using sequential serum samples collected up 94 post symptoms (POS) 65 with real-time quantitative PCR-confirmed infection, we show seroconversion (immunoglobulin (Ig)M, IgA, IgG) >95% cases and neutralizing when sampled...
The SARS-CoV-2 delta (B.1.617.2) variant was first detected in England March, 2021. It has since rapidly become the predominant lineage, owing to high transmissibility. is suspected that associated with more severe disease than previously dominant alpha (B.1.1.7) variant. We aimed characterise severity of compared by determining relative risk hospital attendance outcomes.
Abstract Antibody (Ab) responses to SARS-CoV-2 can be detected in most infected individuals 10-15 days following the onset of COVID-19 symptoms. However, due recent emergence this virus human population it is not yet known how long these Ab will maintained or whether they provide protection from re-infection. Using sequential serum samples collected up 94 post symptoms (POS) 65 RT-qPCR confirmed SARS-CoV-2-infected individuals, we show seroconversion >95% cases and neutralizing antibody...
There is a clear requirement for an accurate SARS-CoV-2 antibody test, both as complement to existing diagnostic capabilities and determining community seroprevalence. We therefore evaluated the performance of variety testing technologies their potential use tools. Highly specific in-house ELISAs were developed detection anti-spike (S), -receptor binding domain (RBD) -nucleocapsid (N) antibodies used cross-comparison ten commercial serological assays—a chemiluminescence-based platform, two...
Human myxovirus resistance 2 (MX2/MXB) is an interferon-induced post-entry inhibitor of human immunodeficiency virus type-1 (HIV-1) infection. While the precise mechanism viral inhibition remains unclear, MX2 localized to nuclear envelope, and blocks import cDNAs. The amino-terminus (N-MX2) essential for anti-viral function, mutation a triple arginine motif at residues 11 13 abrogates anti-HIV-1 activity. In this study, we sought investigate role N-MX2 in activity by identifying functionally...
There is a worldwide need for reagents to perform SARS-CoV-2 detection. Some laboratories have implemented kit-free protocols, but many others do not the capacity develop these and/or manual processing. We provide multiple workflows nucleic acid detection in clinical samples by comparing several commercially available RNA extraction methods: QIAamp Viral Mini Kit (QIAgen), RNAdvance Blood/Viral (Beckman) and Mag-Bind DNA/RNA 96 (Omega Bio-tek). also compared One-step RT-qPCR reagents: TaqMan...
ABSTRACT Human myxovirus resistance 2 (MX2/MXB) is an interferon-stimulated gene (ISG) and was recently identified as a late postentry suppressor of human immunodeficiency virus type 1 (HIV-1) infection, inhibiting the nuclear accumulation viral cDNAs. Although HIV-1 capsid (CA) protein believed to be determinant MX2-mediated inhibition, precise mechanism antiviral action remains unclear. The MX family dynamin-like GTPases also includes MX1/MXA, well-studied inhibitor range RNA DNA viruses,...
Myxovirus resistance 2 (MX2/MXB) is an interferon (IFN)-induced HIV-1 restriction factor that inhibits viral nuclear DNA accumulation. The amino-terminal domain of MX2 binds the capsid and essential for inhibition. Using in vitro assembled Capsid-Nucleocapsid (CANC) complexes as a surrogate lattice, we reveal GTPase (G) contains second, independent capsid-binding site. importance this interaction was addressed competition assays using naturally occurring non-antiviral short isoform lacks 25...
An evaluation of a rapid portable gold-nanotechnology measuring SARS-CoV-2 IgM, IgA and IgG antibody response to spike 1 (S1), 2 (S) nucleocapsid (N) antigens using serum from 74 RNA(+) patients 47 control patients.
Abstract There is a clear requirement for an accurate SARS-CoV-2 antibody test, both as complement to existing diagnostic capabilities and determining community seroprevalence. We therefore evaluated the performance of variety testing technologies their potential tools. A highly specific in-house ELISA was developed detection anti-spike (S), -receptor binding domain (RBD) -nucleocapsid (N) antibodies used cross-comparison ten commercial serological assays – chemiluminescence-based platform,...
ABSTRACT Previous studies showed an increased prevalence of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) thumb subdomain polymorphisms Pro272, Arg277, and Thr286 in patients failing therapy with nucleoside analogue combinations. Interestingly, wild-type HIV-1 BH10 RT contains Thr286. Here, we demonstrate that the presence zidovudine, mutations P272A/R277K/T286A produce a significant reduction viral replication capacity peripheral blood mononuclear cells both absence...
HIV-1 reverse transcriptase (RT) connection subdomain mutations at positions 348, 369 and 376 have been associated with resistance to non-nucleoside RT inhibitors (NNRTIs). N348I may interfere the initiation of (+)-strand DNA synthesis by reducing polypurine tract (PPT) removal in presence nevirapine. The effect NNRTIs on RNase H-mediated cleavage PPT-containing template-primers has studied wild-type mutants N348I, T369I, T369V, T376S N348I/T369I. In NNRTIs, all RTs were able stimulate PPT...
ABSTRACT Human immunodeficiency virus type 1 (HIV-1) infection of dividing and nondividing cells involves regulatory interactions with the nuclear pore complex (NPC), followed by translocation to nucleus preferential integration into genomic areas in proximity inner membrane (INM). To identify host proteins that may contribute these processes, we performed an overexpression screen known membrane-associated NE proteins. We found integral transmembrane SUN1/UNC84A SUN2/UNC84B are potent or...
The clinical relevance of mutations in the connection subdomain and ribonuclease (RNase) H domain HIV-1 reverse transcriptase (RT) is uncertain.The risk virological failure to nonnucleoside RT inhibitor (NNRTI)-based antiretroviral therapy (ART) was evaluated NNRTI-naive patients who started NNRTIs EuroSIDA study after July 1997 according preexisting substitutions RNase RT. An observed association between A376S further investigated by testing vitro NNRTI susceptibility single site-directed...
Abstract There is a worldwide need for reagents to perform SARS-CoV-2 detection. Some laboratories have implemented kit-free protocols, but many others do not the capacity develop these and/or manual processing. We provide multiple workflows nucleic acid detection in clinical samples by comparing several commercially available RNA extraction methods: QIAamp Viral Mini Kit (QIAgen), RNAdvance Blood/Viral (Beckman) and Mag-Bind DNA/RNA 96 (Omega Bio-tek). also compared One-step RT-qPCR...
Productive infection by human immunodeficiency virus type-1 (HIV-1) requires the import of viral replication complexes into nuclei infected cells. Myxovirus resistance 2 (MX2/MxB) blocks this step, halting nuclear accumulation DNA and replication.
During the first wave of global COVID-19 pandemic clinical utility and indications for SARS-CoV-2 serological testing were not clearly defined. The urgency to deploy assays required rapid evaluation their performance characteristics. We undertook an internal validation a CE marked lateral flow immunoassay (LFIA) (SureScreen Diagnostics) using serum from RNA positive individuals pre-pandemic samples. This was followed by delivery same-day named patient serology service LFIA on vetted...
Thymidine analogue resistance mutations (TAMs) selected under treatment with nucleoside analogues generate two distinct genotypic profiles in the HIV-1 reverse transcriptase (RT): (i) TAM1: M41L, L210W and T215Y, (ii) TAM2: D67N, K70R K219E/Q, sometimes T215F. Secondary mutations, including thumb subdomain polymorphisms (e.g. R284K) have been identified association TAMs. We mutational clusters associated virological failure during salvage therapy tenofovir/emtricitabine-based regimens. In...